{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:18:20Z","timestamp":1793452700516,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-022-02490-8","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T22:02:56Z","timestamp":1673388176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Thermal and Hydrolytic Stabilities and Aqueous Solubility of Artesunate for Formulation Studies"],"prefix":"10.1208","volume":"24","author":[{"given":"J. W.","family":"Bezuidenhout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aucamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Stieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Liebenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. K.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"2490_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1365-2125.2006.02673.x","volume":"61","author":"E Hsu","year":"2006","unstructured":"Hsu E. Reflections on the \u2018discovery\u2019 of the antimalarial qinghao. Br J Clin Pharmacol. 2006;61:666\u201370. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02673.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2490_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1586\/eri.09.68","volume":"7","author":"L Cui","year":"2009","unstructured":"Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009;7:999\u20131003. https:\/\/doi.org\/10.1586\/eri.09.68.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2490_CR3","unstructured":"Guoqiao L, Ying L, Zelin L, Meiyi Z. Abstract. In: Guoqiao L, Ying L, Zelin L, Meiyi Z. Cambridge, editors. Artemisinin-based and other antimalarials: detailed account of studies by Chinese scientists who discovered and developed them. Academic Press, Elsevier; 2017 p. 1\u201367."},{"key":"2490_CR4","doi-asserted-by":"publisher","unstructured":"Tiwari MK, Chaudhary S. Artemisinin\u2010derived antimalarial endoperoxides from bench\u2010side to bed\u2010side: chronological advancements and future challenges. Med Res Rev. 2020; 1\u201356. https:\/\/doi.org\/10.1002\/med.21657.","DOI":"10.1002\/med.21657"},{"key":"2490_CR5","doi-asserted-by":"publisher","first-page":"126e139","DOI":"10.1016\/j.pharmthera.2013.12.001","volume":"142","author":"WE Ho","year":"2014","unstructured":"Ho WE, Peh HY, Chan TK, Wong WSF. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther. 2014;142:126e139. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.12.001.","journal-title":"Pharmacol Ther."},{"key":"2490_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.phrs.2016.11.012","volume":"117","author":"CSN Loo","year":"2017","unstructured":"Loo CSN, Lam NSK, Yu D, Su X-Z, Lu F. Artemisinin and its derivatives in treating protozoan infections beyond malaria. Pharmacol Res. 2017;117:192\u2013217. https:\/\/doi.org\/10.1016\/j.phrs.2016.11.012.","journal-title":"Pharmacol Res"},{"key":"2490_CR7","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1007\/s11033-020-05669-z","volume":"47","author":"BH Kiani","year":"2020","unstructured":"Kiani BH, Kayani WK, Khayam AU, Dilshad E, Ismail H, Mirza B. Artemisinin and its derivatives: a promising cancer therapy. Mol Biol Rep. 2020;47:6321\u201336. https:\/\/doi.org\/10.1007\/s11033-020-05669-z.","journal-title":"Mol. Biol. Rep."},{"key":"2490_CR8","doi-asserted-by":"publisher","first-page":"529881","DOI":"10.3389\/fphar.2020.529881","volume":"11","author":"C Xu","year":"2020","unstructured":"Xu C, Zhang H, Mu L, Yang. Artemisinins as anticancer drugs: novel therapeutic approaches, molecular mechanisms, and clinical trials. Front Pharmacol. 2020;11:529881. https:\/\/doi.org\/10.3389\/fphar.2020.529881.","journal-title":"Front. Pharmacol."},{"key":"2490_CR9","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.nano.2015.07.010","volume":"11","author":"A Dwivedi","year":"2015","unstructured":"Dwivedi A, Mazumder A, Du Plessis L, Du Preez JL, Haynes RK, Du Plessis J. In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. Nanomedicine: Nanotechnology. Biol Med. 2015;11:2041\u201350. https:\/\/doi.org\/10.1016\/j.nano.2015.07.010.","journal-title":"Biol Med."},{"key":"2490_CR10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11095-018-2471-9","volume":"35","author":"C Burger","year":"2018","unstructured":"Burger C, Aucamp M, Du Preez J, Haynes RK, Ngwane A, Du Plessis J, et al. Formulation of natural oil nano-emulsions for the topical delivery of clofazimine, artemisone and decoquinate. Pharm Res. 2018;35:186. https:\/\/doi.org\/10.1007\/s11095-018-2471-9.","journal-title":"Pharm Res"},{"issue":"12","key":"2490_CR11","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3109\/03639045.2012.658812","volume":"38","author":"R Chadha","year":"2012","unstructured":"Chadha R, Gupta S, Pathak N. Artesunate-loaded chitosan\/lecithin nanoparticles: preparation, characterization, and in vivo studies. Drug Dev Ind Pharm. 2012;38(12):1538\u201346. https:\/\/doi.org\/10.3109\/03639045.2012.658812.","journal-title":"Drug Dev Ind Pharm"},{"key":"2490_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.2042-7158.1996.tb05870.x","volume":"48","author":"KT Batty","year":"1996","unstructured":"Batty KT, Ilett KF, Davis TME. Chemical stability of artesunate injection and proposal for its administration by intravenous infusion. J Pharm Pharmacol. 1996;48:22\u20136. https:\/\/doi.org\/10.1111\/j.2042-7158.1996.tb05870.x.","journal-title":"J Pharm Pharmacol"},{"key":"2490_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/clpt.2013.26","volume":"93","author":"ICE Hendriksen","year":"2013","unstructured":"Hendriksen ICE, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, et al. Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin Pharmacol Therapeutics. 2013;93:443\u201350. https:\/\/doi.org\/10.1038\/clpt.2013.26.","journal-title":"Clin Pharmacol Therapeutics"},{"key":"2490_CR14","unstructured":"Anon. Guidelines for administration of injectable artesunate for severe malaria. 2014. https:\/\/www.mmv.org\/sites\/default\/files\/uploads\/docs\/access\/Injectable_Artesunate_Tool_Kit\/InjectableArtesunate_posterEN.pdf. Accessed 22 Mar 2022."},{"key":"2490_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1128\/AAC.44.4.972-977.2000","volume":"4","author":"P Newton","year":"2000","unstructured":"Newton P, Supittamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, et al. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother. 2000;4:972\u20137. https:\/\/doi.org\/10.1128\/AAC.44.4.972-977.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"2490_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1475-2875-10-263","volume":"10","author":"CA Morris","year":"2011","unstructured":"Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J. 2011;10:263. https:\/\/doi.org\/10.1186\/1475-2875-10-263.","journal-title":"Malar J"},{"key":"2490_CR17","doi-asserted-by":"publisher","unstructured":"Haynes RK, Chan HW, Cheung MK, Lam WL, Soo MK, Tsang HW, et al. ID. C-10 ester and ether derivatives of dihydroartemisinin: 10-\u03b1 artesunate, preparation of authentic 10-\u03b2 artesunate, and of other esters and ether derivatives bearing potential aromatic intercalating groups at C-10. Eur J Org Chem. 2002; 113\u2013132.\u00a0https:\/\/doi.org\/10.1002\/1099-0690(20021)2002:1<113::AID-EJOC113>3.0.CO;2-N.","DOI":"10.1002\/1099-0690(20021)2002:1<113::AID-EJOC113>3.0.CO;2-N"},{"key":"2490_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4269\/ajtmh.2002.66.130","volume":"66","author":"KT Batty","year":"2002","unstructured":"Batty KT, Ilett KE, Powell SM, Martin J, Davis TME. Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers. Am J Trop Med Hyg. 2002;66:130\u20136. https:\/\/doi.org\/10.4269\/ajtmh.2002.66.130.","journal-title":"Am J Trop Med Hyg"},{"key":"2490_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jopr.2012.11.025","volume":"6","author":"J Agnihotri","year":"2013","unstructured":"Agnihotri J, Singh S, Bigonia P. Formal chemical stability analysis and solubility analysis of artesunate and hydroxychloroquine for development of parenteral dosage form. J Pharm Res. 2013;6:117\u201322. https:\/\/doi.org\/10.1016\/j.jopr.2012.11.025.","journal-title":"J Pharm Res"},{"key":"2490_CR20","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/cmdc.200700064","volume":"2","author":"RK Haynes","year":"2007","unstructured":"Haynes RK, Chan HW, Lung CM, Ng NC, Wong HN, Shek LY, et al. Artesunate and dihydroartemisinin (DHA): unusual decomposition products formed under mild conditions and comments on the fitness of DHA as an antimalarial drug. ChemMedChem. 2007;2:1448\u201363. https:\/\/doi.org\/10.1002\/cmdc.200700064.","journal-title":"ChemMedChem"},{"key":"2490_CR21","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1021\/jm00126a017","volume":"32","author":"AJ Lin","year":"1989","unstructured":"Lin AJ, Lee M, Klayman DL. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 2. Stereospecificity of the ether side chain. J Med Chem. 1989;32:1249\u201352. https:\/\/doi.org\/10.1021\/jm00126a017.","journal-title":"J Med Chem."},{"key":"2490_CR22","unstructured":"Ashford M. Bioavailability \u2013 physicochemical and dosage form factors. In: Aulton ME, Taylor KMG, editors. Aulton\u2019s pharmaceutics: the design and manufacture of medicines. Amsterdam: Elsevier; 2013. p. 314\u201333."},{"key":"2490_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/aps.2012.104","volume":"33","author":"Y Li","year":"2012","unstructured":"Li Y. Qinghaosu (artemisinin): chemistry and pharmacology. Acta Pharmacol Sin. 2012;33:1141\u20136. https:\/\/doi.org\/10.1038\/aps.2012.104.","journal-title":"Acta Pharmacol Sin"},{"key":"2490_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/156802606776743129","volume":"6","author":"RK Haynes","year":"2006","unstructured":"Haynes RK. From artemisinin to new artemisinin antimalarials: biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr Top Med Chem. 2006;6:509\u201337. https:\/\/doi.org\/10.2174\/156802606776743129.","journal-title":"Curr Top Med Chem"},{"key":"2490_CR25","doi-asserted-by":"publisher","first-page":"e00990","DOI":"10.1128\/AAC.00990-21","volume":"65","author":"DJ Watson","year":"2021","unstructured":"Watson DJ, Laing L, Gibhard L, Wong HN, Haynes RK, Wiesner L. Towards new transmission-blocking combination therapies - pharmacokinetics of 10-amino-artemisinins and 11-aza-artemisinin, and comparison with dihydroartemisinin and artemether. Antimicrob Agents Chemother. 2021;65:e00990-e1021. https:\/\/doi.org\/10.1128\/AAC.00990-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"2490_CR26","unstructured":"Pubchem, NIH US National Library of Medicine, National Center for Biotechnology Information. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Artesunic-acid (Accessed 13 May 2022)."},{"key":"2490_CR27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1208\/s12249-015-0311-3","volume":"16","author":"TH Tran","year":"2015","unstructured":"Tran TH, Nguyen TD, Poudel BK, Nguyen HT, Kim JO, Yong CS, et al. Development and evaluation of artesunate-loaded chitosan-coated lipid nanocapsule as a potential drug delivery system against breast cancer. AAPS PharmSciTech. 2015;16:1307\u201316. https:\/\/doi.org\/10.1208\/s12249-015-0311-3.","journal-title":"AAPS PharmSciTech"},{"key":"2490_CR28","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1021\/acs.jced.8b00988","volume":"64","author":"R Xu","year":"2019","unstructured":"Xu R, Han T, Shen L, Zhao J, Lu X. Solubility determination and modelling for artesunate in binary solvent mixtures of methanol, ethanol, isopropanol and propylene glycol and water. J Chem Eng Data. 2019;64:755\u201362. https:\/\/doi.org\/10.1021\/acs.jced.8b00988.","journal-title":"J Chem Eng Data"},{"key":"2490_CR29","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1021\/jm00394a037","volume":"30","author":"AJ Lin","year":"1987","unstructured":"Lin AJ, Klayman DL, Milhous WK. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. J Med Chem. 1987;30:2147\u201350. https:\/\/doi.org\/10.1021\/jm00394a037.","journal-title":"J Med Chem"},{"key":"2490_CR30","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/hlca.19840670615","volume":"67","author":"XD Luo","year":"1984","unstructured":"Luo XD, Yeh HJC, Brossi A, Flippen-Anderson JL. Gillardi R The chemistry of drugs part IV: configurations of antimalarials derived from qinghaosu: dihydroqinghaosu, artemether, and artesunic acid. Helv Chim Acta. 1984;67:1515\u201322. https:\/\/doi.org\/10.1002\/hlca.19840670615.","journal-title":"Helv Chim Acta"},{"key":"2490_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2125.2004.02045.x","volume":"57","author":"KT Batty","year":"2004","unstructured":"Batty KT, Ilett KF, Davis TME. Protein binding and \u03b1:\u03b2 anomer ratio of dihydroartemisinin in vivo. Br J Clin Pharmacol. 2004;57:529\u201333. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02045.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2490_CR32","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1021\/jo102392p","volume":"76","author":"W Cabri","year":"2011","unstructured":"Cabri W, ID\u2019Acquarica I, Simone P, Di Iorio M, Di Mattia M Gasparrini F, et al. Stereolability of dihydroartemisinin, an antimalarial drug a comprehensive kinetic investigation. Part 2 J Org Chem. 2011;76:4831\u201340. https:\/\/doi.org\/10.1021\/jo102392p.","journal-title":"Part 2. J Org Chem."},{"key":"2490_CR33","unstructured":"The International Pharmacopoeia 10th Edition 2020; Monographs, pharmaceutical substances.\u00a0https:\/\/digicollections.net\/phint\/2020\/index.html#d\/b.6.1.30 (accessed 13 May 2022)."},{"key":"2490_CR34","unstructured":"European Medicines Agency. Stability testing of new drug substances and products Q1A(R2); Q1A(R2) Stability Testing of New Drug Substances and Products. In: Guidance Document: International Conference on Harmonisation. International Conference on Harmonisation. https:\/\/www.ema.europa.eu\/en\/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline. Accessed 22 Mar 2022."},{"key":"2490_CR35","unstructured":"The International Pharmacopoeia 10th Edition 2021. https:\/\/www.gmp-compliance.org\/gmp-news\/10th-edition-of-the-international-pharmacopoeia. Accessed 13 May 2022."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-022-02490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-022-02490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T14:12:29Z","timestamp":1714745549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-022-02490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["2490"],"URL":"https:\/\/doi.org\/10.1208\/s12249-022-02490-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Any opinions, findings and conclusions, or recommendations expressed in this material are those of the authors and therefore the NRF does not accept any liability in regard thereto.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"33"}}